1. Home
  2. RFL vs NYXH Comparison

RFL vs NYXH Comparison

Compare RFL & NYXH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Rafael Holdings Inc. Class B

RFL

Rafael Holdings Inc. Class B

HOLD

Current Price

$1.26

Market Cap

133.1M

Sector

Finance

ML Signal

HOLD

Logo Nyxoah SA

NYXH

Nyxoah SA

BUY

Current Price

$0.81

Market Cap

137.5M

Sector

Health Care

ML Signal

BUY

Company Overview

Basic Information
Metric
RFL
NYXH
Founded
2017
2009
Country
United States
Belgium
Employees
N/A
N/A
Industry
Real Estate
Medical/Dental Instruments
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
133.1M
137.5M
IPO Year
2017
2021

Fundamental Metrics

Financial Performance
Metric
RFL
NYXH
Price
$1.26
$0.81
Analyst Decision
Buy
Analyst Count
0
4
Target Price
N/A
★ $4.20
AVG Volume (30 Days)
132.6K
★ 202.7K
Earning Date
12-10-2026
11-05-2026
Dividend Yield
N/A
N/A
EPS Growth
★ 28.28
N/A
EPS
N/A
★ N/A
Revenue
★ $917,000.00
N/A
Revenue This Year
N/A
$275.91
Revenue Next Year
N/A
$93.27
P/E Ratio
★ N/A
N/A
Revenue Growth
★ 43.96
N/A
52 Week Low
$1.12
$0.88
52 Week High
$3.96
$5.92

Technical Indicators

Market Signals
Indicator
RFL
NYXH
Relative Strength Index (RSI) 30.27 21.60
Support Level $1.24 N/A
Resistance Level $1.37 $1.69
Average True Range (ATR) 0.10 0.06
MACD -0.01 -0.05
Stochastic Oscillator 7.50 2.86

Price Performance

Historical Comparison
RFL
NYXH

About RFL Rafael Holdings Inc. Class B

Rafael Holdings Inc is a biotechnology firm that develops pharmaceuticals and invests in clinical and early-stage companies in pharmaceuticals and medical devices. Trappsol Cyclo is in Phase 3 trials for Niemann-Pick Disease Type C1. The company focuses on completing these trials, seeking regulatory approval, and commercializing the product. It also invests in portfolio companies including Cyclo, LipoMedix, Barer, Rafael Medical Devices, Cornerstone, and Day Three, targeting therapeutics for unmet medical needs. The business operates through three segments: Healthcare, Infusion Technology, and Real Estate. Operations are based in the United States and Israel.

About NYXH Nyxoah SA

Nyxoah SA is a health-technology company focused on the development and commercialization of solutions and services to treat sleep-disordered breathing conditions. The company's solution platform is based on the Genio system, a CE-Mark validated, user-centered, bilateral neurostimulation therapy to treat moderate to severe Obstructive Sleep Apnea (OSA), the common sleep disordered breathing condition that is associated with increased mortality risk and comorbidities including cardiovascular diseases, depression and stroke.

Share on Social Networks: